Walser Wealth Management Company A Ltd Liability Co Buys Shares of 1,613 Amgen Inc. $AMGN

Walser Wealth Management Company A Ltd Liability Co bought a new stake in Amgen Inc. (NASDAQ:AMGN) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 1,613 shares of the medical research company’s stock, valued at approximately $528,000.

Several other large investors have also modified their holdings of AMGN. Vanguard Group Inc. raised its position in Amgen by 1.8% during the 4th quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock worth $17,949,296,000 after buying an additional 961,975 shares during the last quarter. State Street Corp boosted its holdings in shares of Amgen by 4.4% in the fourth quarter. State Street Corp now owns 30,591,403 shares of the medical research company’s stock valued at $10,012,872,000 after acquiring an additional 1,287,310 shares in the last quarter. Capital World Investors increased its stake in shares of Amgen by 22.9% during the fourth quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock worth $7,560,249,000 after acquiring an additional 4,302,237 shares during the period. Capital International Investors increased its stake in shares of Amgen by 1.5% during the third quarter. Capital International Investors now owns 19,192,995 shares of the medical research company’s stock worth $5,414,296,000 after acquiring an additional 282,219 shares during the period. Finally, Geode Capital Management LLC increased its stake in shares of Amgen by 7.8% during the fourth quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock worth $4,665,822,000 after acquiring an additional 1,035,779 shares during the period. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Insiders Place Their Bets

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the company’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the sale, the senior vice president owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.85% of the company’s stock.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $337.60 on Friday. The firm has a market capitalization of $182.21 billion, a price-to-earnings ratio of 23.49, a price-to-earnings-growth ratio of 3.43 and a beta of 0.42. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01. The business’s 50 day simple moving average is $340.96 and its 200-day simple moving average is $345.81. Amgen Inc. has a 12 month low of $267.83 and a 12 month high of $391.29.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $4.77 by $0.38. The firm had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.Amgen’s quarterly revenue was up 5.8% on a year-over-year basis. During the same period last year, the business posted $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, equities analysts forecast that Amgen Inc. will post 22.38 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the stock. Daiwa Securities Group reduced their price objective on shares of Amgen from $410.00 to $390.00 and set an “outperform” rating for the company in a research report on Wednesday, May 13th. Jefferies Financial Group began coverage on Amgen in a research report on Tuesday, March 10th. They set a “hold” rating and a $350.00 target price on the stock. Freedom Capital upgraded Amgen from a “hold” rating to a “strong-buy” rating in a research report on Thursday, May 7th. Barclays assumed coverage on Amgen in a research note on Friday, February 20th. They set an “equal weight” rating and a $350.00 target price for the company. Finally, Argus reduced their price target on Amgen from $400.00 to $375.00 and set a “buy” rating for the company in a report on Wednesday, May 20th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, fifteen have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Amgen currently has an average rating of “Hold” and an average target price of $354.42.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.